Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS

Oculis and the National Multiple Sclerosis Society’s campaign share a common goal to accelerate breakthroughs in MS research and improve patients’ quality of life

ZUG, Switzerland, October 1, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology, is partnering with the National Multiple Sclerosis Society on its Campaign to End MS, as the industry partner focusing on Vision, officially launching today, on October 1, 2026. This 5-year campaign aims to accelerate research breakthroughs, improve access to care, and create a future where no one lives with the uncertainty of multiple sclerosis (MS). By bringing together people affected by MS, researchers, healthcare leaders, advocates, and supporters, the campaign seeks to translate scientific progress into meaningful advances in treatment and care, while strengthening the resources and support available to the MS community. Oculis’ sponsorship reflects a shared commitment to advancing innovation, addressing unmet needs, and improving the lives of people affected by MS.